Gossamer Bio, Inc.

GOSSNASDAQHealthcare● Active

$0.16

$-0.01(-5.77%)

Market Cap$38701417

P/E Ratio—

52W High$3.87

52W Low$0.163

Avg Volume10.6M

Open$0.18

Beta2.00

Free Cash Flow Financials Revenue

Gossamer Bio, Inc. (GOSS) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

GOSS · free cash flow · updated Jun 8, 2026

Core FCF metrics

GOSS · FCF · TTM · margin & CAGR

Free cash flow was −$171.3M for FY2025 (fiscal year ending 2025-12-31), down 4840.7% year-over-year The FCF margin was -353.5%.

FY2025 Free Cash Flow−$171.3M▼ -4840.7% YoY

Trailing 12M (TTM)−$170.3Mtrailing 4 quarters sum

FCF Margin-353.5%−$171.3M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

GOSS · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$171.3M(0M)−$171.3M▼ 4840.7%-353.5%

FY2024−$3.5M(0M)−$3.5M▲ +97.8%-3.0%

FY2023−$159.2M(0M)−$159.2M▲ +15.1%—

FY2022−$187.0M(0M)−$187.5M▲ +1.6%—

FY2021−$188.9M(2M)−$190.5M▲ +5.3%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

GOSS · P/FCF · FCF yield · FCF per share

Gossamer Bio, Inc. (GOSS) reported negative free cash flow of −$0.17B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

GOSS · cash flow statement · operating / investing / financing

For FY2025, Gossamer Bio, Inc. generated −$171.3M in operating cash flow and spent 0M in capital expenditures, yielding −$171.3M in free cash flow.

Operating Activities

−$171.3M

Cash from core business operations

2025-12-31

Investing Activities

+$156.4M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$6.4M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$171.3M) − |CapEx| (0M) = FCF (−$171.3M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

GOSS vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Gossamer Bio, Inc.YOU

GOSS

−$171.3M-4840.7%-353.5%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Gossamer Bio, Inc. (GOSS) reported free cash flow of −$171.3M for FY2025 (fiscal year ending 2025-12-31), down 4840.7% year-over-year. The FCF margin was -353.5%.

Based on available data, Gossamer Bio, Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $20,000 in FY2016.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

GOSS free cash flow · 8 questions

Gossamer Bio, Inc. free cash flow was −$171.3M for FY2025, down 4840.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$170.3M.

GOSS free cash flowGOSS FCFGOSS FCF 2025GOSS free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Gossamer Bio, Inc. · Gossamer Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026